Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Huntington disease (HD) is an inherited, fatal neurodegenerative disease with no disease-modifying therapy currently available. In addition to characteristic motor deficits and atrophy of the caudate nucleus, signature hallmarks of HD include behavioral abnormalities, immune activation, and cortical and white matter loss. The identification and validation of novel therapeutic targets that contribute to these degenerative cellular processes may lead to new interventions that slow or even halt the course of this insidious disease. Semaphorin 4D (SEMA4D) is a transmembrane signaling molecule that modulates a variety of processes central to neuroinflammation and neurodegeneration including glial cell activation, neuronal growth cone collapse and apoptosis of neural precursors, as well as inhibition of oligodendrocyte migration, differentiation and process formation. Therefore, inhibition of SEMA4D signaling could reduce CNS inflammation, increase neuronal outgrowth and enhance oligodendrocyte maturation, which may be of therapeutic benefit in the treatment of several neurodegenerative diseases, including HD. To that end, we evaluated the preclinical therapeutic efficacy of an anti-SEMA4D monoclonal antibody, which prevents the interaction between SEMA4D and its receptors, in the YAC128 transgenic HD mouse model. Anti-SEMA4D treatment ameliorated neuropathological signatures, including striatal atrophy, cortical atrophy, and corpus callosum atrophy and prevented testicular degeneration in YAC128 mice. In parallel, a subset of behavioral symptoms was improved in anti-SEMA4D treated YAC128 mice, including reduced anxiety-like behavior and rescue of cognitive deficits. There was, however, no discernible effect on motor deficits. The preservation of brain gray and white matter and improvement in behavioral measures in YAC128 mice treated with anti-SEMA4D suggest that this approach could represent a viable therapeutic strategy for the treatment of HD. Importantly, this work provides in vivo demonstration that inhibition of pathways initiated by SEMA4D constitutes a novel approach to moderation of neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Basal Ganglia and Adaptive Motor Control
Graybiel, A. M., Aosaki, T., Flaherty, A. W., & Kimura, M. (1994) · Science · doi:10.1126/science.8091209 · Cited by 1,324
Tabrizi, S. J., Langbehn, D. R., Leavitt, B. R., Roos, R. A., Durr, A., Craufurd, D., Kennard, C., Hicks, S. L., Fox, N. C., Scahill, R. I., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70170-x · Cited by 984
Neurogenesis in the striatum of the adult human brain
Ernst, A., Alkass, K., Bernard, S., Salehpour, M., Perl, S., Tisdale, J., Possnert, G., Druid, H., & Frisén, J. (2014) · Cell · doi:10.1016/j.cell.2014.01.044 · Cited by 937
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848 · cited 1×
“…diminished neurotrophin levels, transcriptional dysregulation, disruption of axonal transport, and excitotoxicity, while extrinsic mechanisms include astrocyte and oligodendrocyte dysfunction, microglial activation , and abnormal cortical neuron function (Ehrlich, 2012; Zuccato et al., 2010).”
Regional and cellular gene expression changes in human Huntington's disease brain
Hodges, A., Strand, A. D., Aragaki, A. K., Kuhn, A., Sengstag, T., Hughes, G., Elliston, L. A., Hartog, C., Goldstein, D. R., Thu, D., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl013 · Cited by 804
Semaphorins and their receptors in immune cell interactions
Suzuki, K., Kumanogoh, A., & Kikutani, H. (2008) · Nature Immunology · doi:10.1038/ni1553 · Cited by 400
Okuno, T., Nakatsuji, Y., Moriya, M., Takamatsu, H., Nojima, S., Takegahara, N., Toyofuku, T., Nakagawa, Y., Kang, S., Friedel, R. H., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903302 · Cited by 119
Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer’s disease
Lassmann, H. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0607-8 · Cited by 112 · cited 1×
“Considering the convergent pathogenic pathways of neuroinflammatory and neurodegenerative diseases (Borjabad and Volsky, 2012; Ehrnhoefer et al., 2011; Ellwardt and Zipp, 2014; Lassmann, 2011), anti-SEMA4D treatment may have benefits in other indications, including Huntington disease (HD).”
Neurovascular abnormalities in humans and mice with Huntington's disease
Lin, C.-Y., Hsu, Y.-H., Lin, M.-H., Yang, T.-H., Chen, H.-M., Chen, Y.-C., Hsiao, H.-Y., Chen, C.-C., Chern, Y., & Chang, C. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.08.019 · Cited by 98
Cited by
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
“In the YAC128 transgenic HD mouse model, treatment with an anti-SEMA4D monoclonal antibody reduced brain atrophy, improved cognition, and reduced anxiety-like behavior.(528) These findings suggest that targeting microglia could be a promising direction in exploring treatments for HD.”
BackgroundHuntingtin suppression restores cognitive function in a mouse model of Huntington’s disease
Southwell, A. L., Kordasiewicz, H. B., Langbehn, D., Skotte, N. H., Parsons, M. P., Villanueva, E. B., Caron, N. S., Østergaard, M. E., Anderson, L. M., Xie, Y., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3959 · Cited by 126
“The integrated optical density of striatal staining was quantified in each brain as previously described (43) and normalized to the mean value for PBS-treated Hu18/18 mice stained together.”
MethodSelf-citationNeuroinflammation in Huntington’s Disease: A Starring Role for Astrocyte and Microglia
Saba, J., Couselo, F. L., Bruno, J., Carniglia, L., Durand, D., Lasaga, M., & Caruso, C. (2022) · Current Neuropharmacology · doi:10.2174/1570159x19666211201094608 · Cited by 117
“Anti-SEMA4D antibody ameliorates the pathological features of HD, such as striatal and cortical atrophy, and improves behavioral symptoms in YAC128 mice; however, it has no effect on motor dysfunction [288].”
Neuroinflammation in Huntington’s disease: From animal models to clinical therapeutics
Jia, Q., Li, S., Li, X.-J., & Yin, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1088124 · Cited by 70
Feigin, A., Evans, E. E., Fisher, T. L., Leonard, J. E., Smith, E. S., Reader, A., Mishra, V., Manber, R., Walters, K. A., Kowarski, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01919-8 · Cited by 67
Self-citationSemaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity
Evans, E. E., Mishra, V., Mallow, C., Gersz, E. M., Balch, L., Howell, A., Reilly, C., Smith, E. S., Fisher, T. L., & Zauderer, M. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02509-8 · Cited by 44
Self-citation
Metadata
- Authors
- Southwell, A. L., Franciosi, S., Villanueva, E. B., Xie, Y., Winter, L. A., Veeraraghavan, J., Jonason, A., Felczak, B., Zhang, W., Kovalik, V., Waltl, S., Hall, G., Pouladi, M. A., Smith, E. S., Bowers, W. J., Zauderer, M., & Hayden, M. R.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 76
- Pages
- 46-56
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2028349138
- Cited by
- 109
- References
- 9
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.